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ABSTRACT 
 
Manganese(III) porphyrins (MnPs) are superoxide dismutase (SOD) mimics with 
demonstrated beneficial effects in cancer treatment in combination with chemo- and 
radiotherapy regimens. Despite the ongoing clinical trials, little is known about the 
effect of MnPs on metastasis, being therefore essential to understand how MnPs 
affect this process. In the present work, the impact of the MnP MnTnHex-2-PyP5+ in 
metastasis-related processes was assessed in breast cancer cells (MCF-7 and MDA-
MB-231), alone or in combination with doxorubicin (dox). The co-treatment of cells 
with non-cytotoxic concentrations of MnP and dox altered intracellular ROS, 
increasing H2O2. While MnP alone did not modify cell migration, the co-exposure led 
to a reduction in collective cell migration and chemotaxis. In addition, the MnP 
reduced the dox-induced increase in random migration of MDA-MB-231 cells. 
Treatment with either MnP or dox decreased the proteolytic invasion of MDA-MB-231 
cells, although the effect was more pronounced upon co-exposure with both 
compounds. Moreover, to explore the cellular mechanisms underlying the observed 
effects, cell adhesion, spreading, focal adhesions, and NF-kB activation were also 
studied. Although differential effects were observed according to the endpoints 
analyzed, overall, the alterations induced by MnP in dox-treated cells were 
consistently with a therapeutically favorable outcome. 
 
 
 
GRAPHICAL ABSTRACT (See Figures file) 
 
 
HIGHLIGHTS 
 
· MnPs are SOD mimics with potential therapeutic applications in cancer 
· The impact of an MnP in breast cancer metastasis-related processes was 
assessed 
· Treatment with MnP+dox decreased collective cell migration, chemotaxis and 
invasion 
· MnP also reduced the dox-induced increase in random migration of MDA-MB-231 
cells 
· Combination of MnP with dox revealed therapeutically favorable effects 
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ABBREVIATIONS 
 CAT, catalase; CV, crystal violet; DAPI, 4`,6-diamino-2-phenylindole; DHE, 
dihydroethidium; DHR, dihydrorhodamine 123; DMEM, Dulbecco’s Modified Eagle’s 
Medium; DMSO, dimethylsulfoxide; dox, doxorubicin; ECM, extracellular matrix; 
EDTA, ethylenediaminetetraacetic acid; FA, focal adhesions; FAK, focal adhesion 
kinase; FBS, foetal bovine serum; GAPDH, glyceraldehyde 3-phosphate 
dehydrogenase; IB, immunoblotting; MnP, Manganese(III) porphyrin; MnTnHex-2-
PyP5+, Mn(III) 5,10,15,20-meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin (charges 
are omitted throughout the text for clarity); MMPs, matrix metalloproteinases; 
MnSOD, Manganese-superoxide dismutase (SOD2); MTT, 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl-2H-tetrazolium bromide; NF-kB, nuclear factor kappa B; PBS, 
phosphate buffered saline; PFA, paraformaldehyde; PI, propidium iodide; ROS, 
reactive oxygen species; SDS, sodium dodecyl sulfate; SOD, superoxide dismutase; 
SODm, superoxide dismutase mimics; TNF-α, Tumor Necrosis Factor-α  
 
 
 
INTRODUCTION 
Superoxide dismutase mimics (SODm) are described as a group of synthetic 
compounds that possess the ability to mimic the functional properties of native 
superoxide dismutases. SODm are catalytical polyfunctional antioxidants, being thus 
effective not only in the disproportionation of superoxide anion but also in the 
elimination of other reactive species [1]. Moreover, SODm may also interact with 
redox domains of several signalling proteins involved in cancer development [1]. 
Notably, SODm have repeatedly demonstrated beneficial effects in different in vitro 
and in vivo experimental models of several human pathologies, including 
cardiovascular, neurodegenerative, and inflammatory diseases as well as different 
types of cancer [2,3]. There is growing evidence that SODm have indeed several 
features that can be valuable for cancer treatment. In this context, Manganese 
Porphyrins (MnPs) have been pointed out as one of the most promising classes of 
SODm [1]. We [4,5] have recently addressed the rational for the use of SODm in 
cancer therapy. Due to the differential effects of SOD in nontumor vs tumor cells, 
several reports have demonstrated the usefulness of SODm, including MnPs, either 
as protectors of normal cells against radio- and chemotherapy or as prototype drugs 
to impair cancer cell proliferation. As a consequence, some SODm are currently 
being evaluated in cancer clinical trials, in combination with chemo- or radiotherapy 
regimens [1,4]. Despite all the evidences supporting a role for SODm in cancer 
therapy, the effect of such compounds in metastasis is still almost unexplored. It is 
accepted that ROS can regulate key cellular mechanisms involved in cancer cell 
migration/invasion, including invadopodia formation, MMP activation/expression, 
focal adhesion dynamics, cell-cell contact, cytoskeleton remodelling, and gene 
expression [4]. SODm may therefore also impact cancer metastasis.  
Although elevating SOD enzymes levels generally inhibits tumour invasiveness, 
some reports show the opposite effect [6]. In the case of breast cancer, MnSOD can 
have a dual role in tumorigenic progression [5]. While at an early cancer stage 
MnSOD can work as a caretaker gene [7], the expression and activity levels of this 
enzyme have been shown to enhance breast cancer metastatic phenotype [8]. 
Considering this dual effect of SOD in breast cancer progression along with the 
previous in vitro and in vivo studies that suggest the potential use of SODm in breast 
cancer treatment [5], it is essential to explore the impact of SODm in cell processes 
related with metastases. This information will be important to exclude potential 
detrimental effects related with cell migration, in case of a future application of SODm 
in breast cancer treatment. 
In this context, the present report addresses the effect of MnTnHex-2-PyP5+ (Fig. 1), 
a promising SODm [1] in human breast cancer cells with low (MCF7) and high (MDA-
MB-231) aggressiveness. The innovative aspects of this work include the evaluation 
of the impact of the MnP in several types of cell migration in cells treated with 
doxorubicin (dox), a widely used chemotherapy drug for metastatic breast cancer. In 
the present report, SODm exhibited beneficial effects in reducing the migration of 
dox-treated cells. Furthermore, to explore the cellular mechanisms underlying the 
observed effects, several aspects related with the migratory phenotype were studied.  
 
 
 
 
MATERIAL AND METHODS 
 
Chemicals  
 
Dulbecco´s Modified Eagle’s Medium (DMEM), foetal bovine serum (FBS), penicillin-
streptomycin solution, insulin solution from bovine pancreas, trypsin, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), crystal violet, dox, 
catalase (CAT), EDTA, PFA, RNase A, DAPI, glutaraldehyde (25% commercial 
solution,) NaBH4 and TNF-a were purchased from Sigma-Aldrich (St Louis, MO, 
USA). Dimethylsulfoxide (DMSO), propidium iodide (PI), ethanol and acetic acid 
were purchased from Merck (Darmstadt, Germany). Acetic acid glacial and NaCl 
were purchased from Panreac (Barcelona, Spain). MatrigelTM was purchased from 
BD Biosciences (San Jose, CA, USA). Oregon Green 488-conjugated gelatin was 
acquired from Life Technologies (Oregon, USA). Dihydrorhodamine 123 (DHR) and 
dihydroethidium (DHE) probes were purchased from Molecular Probes (Eugene, OR, 
USA). For these probes, 10 mM stock solutions were prepared in DMSO, aliquoted 
and stored under nitrogen at – 20 ºC. MnTnHex-2-PyP5+ was synthesized and 
characterized as described by Batinic-Haberle et al [9]. Mowiol 4-88 and antibodies 
anti-vinculin, anti-FAK and anti-Tubulin were obtained from EMD Millipore 
(Burlington, Massachusetts, USA). NuPAGE®Novex 4-12 % Bis-Tris gels, primary 
antibody anti-pFAK Y397 and secondary antibody conjugated to Alexa Fluor 488 
were obtained from Invitrogen (Grand Island, NY, USA). Antibodies anti-Paxillin and 
anti-GAPDH were obtained from Cell Signaling Technology (Danvers, MA, USA). 
RIPA buffer was purchased from Roche (Basel, Switzerland). pTK-Renilla luciferase 
and passive lysis buffer 5X were obtained from Promega (Madison, WI, USA). 
Lipofectamine® LTX Reagent and PLUSTM Reagent were purchased from 
ThermoFisher Scientific (Carlsbad, California, USA). 
 
Cell culture 
Human breast cancer cell lines MDA-MB-231 and MCF7 were obtained from ATCC 
and DSMZ, respectively. Both cell lines were kept in DMEM supplemented with 10% 
FBS, 100 U/mL penicillin and 0.1 mg/mL streptomycin. MCF7 cells medium was 
additionally supplemented with 0.1% insulin. Cultures were kept at 37 °C, under a 
humidified atmosphere containing 5% CO2. 
 
Cell viability assay 
The effect of MnTnHex-2-PyP in cell viability, either given alone or in combination 
with dox, was determined by the MTT assay. Briefly, 6.5 ´ 103 cells (for MCF7) or 5 ´ 
103 cells (for MDA-MB-231) were cultured in 200 mL of complete medium in 96-well 
plates. The cells were grown for 48 h and then exposed to different concentrations of 
dox (0.5-5 mM for MCF7 cells and 0.5-20 mM for MDA-MB-231 cells), alone or in 
combination with MnTnHex-2-PyP (5 µM), for a 24 h-period. MTT reduction assay 
was performed as previously described by Fernandes et al. [10]. Two to ten 
independent experiments were performed, and four replicate cultures were used for 
each condition.  
 Cell cycle analysis 
The effect of MnTnHex-2-PyP on cell cycle distribution and cell death was analysed 
by PI staining of fixed cells. MDA-MB-231 and MCF7 cells were seeded in 6-well 
plates in complete growth medium. Twenty-four h later cells were exposed to vehicle, 
dox (0.1 mM), MnTnHex-2-PyP (5 µM), or both drugs for 16 h at 37 °C in complete 
medium. Both floating and adherent cells were collected using 5 mM EDTA in PBS. 
Cells were washed with cold PBS and fixed with cold 80% ethanol. Cells were 
resuspended in PBS with 1% FBS and after RNase A-treatment (50 µg/mL; Sigma-
Aldrich, St Louis, MO, USA) and PI (25 µg/mL) staining for 15-20 min, cell DNA 
content was analysed using a FACSCalibur flow cytometer (BD). Data acquisition 
and analysis were performed using CellQuest software (BD) and FlowJo (Tree Star, 
San Carlos, Calif.), respectively. 
 
Intracellular ROS measurement 
The intracellular ROS levels were assessed by fluorescence microscopy using two 
different probes: dihydroethidium (DHE) and dihydrorhodamine 123 (DHR) [11,12]. 
For ROS assays, MDA-MB-231 and MCF7 cells were seeded on MatrigelTM- coated 
(1/30 dilution in FBS-free medium) dishes and after 24 h, when cells were ~40 % 
confluent they were incubated with vehicle, dox (0.1 µM), MnTnHex-2-PyP (5 µM) or 
both drugs for 16 h at 37 °C in FBS-free medium. For the DHR assays, CAT (50 
U/mL) was used alone or in combination with both drugs. Cells were then washed 
with warm PBS and incubated with DHR or DHE (10 µM) in FBS-free medium for 25 
min at 37 °C. Cell image acquisition was performed using a wide field BX51 
fluorescent Olympus microscope with a 40x objective using a 460-490 nm/<520 nm 
excitation/emission filter for DHR and a 520–550 nm/<580 nm excitation/emission 
filter for DHE. Cell fluorescence and area were determined using ImageJ (National 
Institutes of Health) [13] for a minimum of 45 cells per condition. Three to four 
independent experiments were performed.  
 
In vitro wound-healing assay 
The in vitro wound-healing assay was optimized according to Liang et al. [14]. MCF7 
cells and MDA-MB-231 cells were seeded in 24-well plate with an inoculum of 2 × 
105 cells per well and cultured in complete media for 24 h. After 24 h, media was 
removed, and each well was scratched using a 200 μL pipette tip, leaving a gap of 
approximately 0.8 mm in width. Cells were washed twice with PBS to remove 
detached cells and cell debris. Cells were kept in FBS- and insulin-free media 
containing the test compounds. The distance between the two limits of the scratch 
was monitored using a Motic AE 2000 inverted microscope with an objective of 10x 
at 0, 9, and 24 h after compounds addition. Images were collected using a Moticam 
2500 and measurements were performed using Motic Images Plus V2.0 software. 
Zero h was considered as 0% of wound closure. At each time point one photo of 
each scratch was taken and three representative measures were performed. Each 
assay was performed with intern triplicates and at least 4 independent experiments 
were performed per condition.  
 
Chemotaxis and chemoinvasion assays 
The chemotactic migration of MCF7 and MDA-MB-231 cells was evaluated in 24-well 
plates with transwell inserts with transparent PET membranes containing 8 mm pores 
(BD Falcon, USA). Cells (1 x 105 cells in 200 mL of FBS-free medium) were seeded 
on the top of the insert and complete medium was placed in the lower chamber of the 
culture well. The test compounds were added to both chambers and cultures were 
incubated for 16 h. Non-migrating cells were removed from the upper side of the 
inserts with a cotton swab. Cells that migrated to the underside of the inserts were 
fixed with cold 96% ethanol and stained with 0.1% CV in 10% ethanol. Cells were 
resuspended in 96% ethanol with 1% acetic acid and the absorbance at 595 nm was 
measured in a Thermo Fisher Multiskan FC microplate reader. Three to five 
independent experiments were performed. 
The chemoinvasion assay was performed as described for chemotaxis 
measurements, but herein the membrane filter was overlaid with MatrigelTM diluted in 
serum-free medium (1/30), which blocked non-invasive cells from migrating through 
[15,16]. Three to five independent experiments were performed. 
 
Random cell migration assay 
Individual random cell migration of MDA-MB-231 and MCF7 cells was evaluated by 
time-lapse microscopy as previously described by Saraiva et al. [17]. Briefly, MDA-
MB-231 or MCF7 cells were seeded at low density (30% confluent) on MatrigelTM-
coated 12-well plates. Drugs were added, and cells were allowed to adhere for 4 h at 
37 ºC. Individual cells were imaged at 10-min intervals for 12 h with a wide-field 
microscope (Observer.Z1; CarlZeiss) contained within an environmental chamber at 
37 °C using a 10x objective and a camera (AxioCam HRm; Carl Zeiss). Migration 
tracks were generated using the ImageJ Manual Tracking plugin, and tracks were 
analysed using an in house-written Mathematica 7 notebook (provided by G. Dunn, 
King`s College London, London, England, UK) to calculate migration rates and 
persistence. 
 
Gelatin Degradation Assay 
Fluorescent gelatin-coated cover slips were prepared as described by Martin et al. 
[18]. Briefly, coverslips were coated with thin layers of Oregon Green 488-conjugated 
gelatin, cross-linked with 0.5% glutaraldehyde for 15 min, incubated for 3 min at 
room temperature with 5 mg/ml NaBH4 and washed three times with PBS and 
incubated for 15 min in 70% ethanol. Cells were seeded on gelatin-coated coverslips 
at a density of 4 x 104 cells per well in complete DMEM and incubated with the 
relevant compounds. After 16 h cells were fixed in 4% PFA. Analysis was performed 
on a wide field BX51 fluorescent Olympus microscope with a 40x objective. The 
gelatine degradation percentage (per image) was measured using Image J software 
and was then normalized to the number of cells to obtain normalized degradation 
value. 
 
Cell detachment assay 
Cell detachment was analysed using an EDTA-induced cell detachment assay as 
previously described by Saraiva et al. [17]. Briefly, MDA-MB-231 or MCF7 cells were 
seeded in 24-well plates for 24 h until cells reached ~30% confluency. Cells were 
incubated with vehicle, dox (0.1 µM), MnTnHex-2-PyP (5 µM) or both drugs for 24 h, 
at 37 °C in complete cell culture medium. After treatment, cells were washed with 
PBS, incubated with PBS-EDTA (1 mM) or cell media for 10 min at 37 °C and 
washed with PBS to remove non-adherent cells. The remaining adherent cells were 
fixed using 4% PFA and stained with 0.1% CV in 10% ethanol. The wells were 
washed with water, and the dye was eluted using 1% acetic acid in 96% ethanol. 
Absorbance was measured at 595 nm on a Multiskan FC (Thermo Fisher Scientific) 
microplate reader. Three independent experiments were performed. 
 
Cell spreading assay 
Cell spreading evaluation was performed similarly as previously described by 
Saraiva et al. [17]. MDA-MB-231 and MCF7 cells were detached with trypsin, 
resuspended in complete medium and incubated for 30 min or 16 h with the 
appropriate drugs. Cells were seeded in MatrigelTM-coated coverslips and left to 
attach for 20 min, 35 min and 12 h or 3 h and 12 h, for MDA-MB-231 and MCF7, 
respectively. Cells were fixed with 4% PFA, washed with PBS and the coverslips 
were mounted in Mowiol 4-88 containing DAPI. Image acquisition was performed a 
wide field BX51 fluorescent Olympus microscope with a 40x objective. Cell area was 
determined using Image J. Mean cell areas were normalized to the untreated control 
at 12 h and were plotted against time. Three independent experiments were 
performed for each protocol. 
 
Focal adhesion number 
MDA-MB-231 or MCF7 cells were seeded in MatrigelTM –coated coverslips so that 
they would reach 30-40% confluence 40 h later. Drugs were added to cells 24 h post 
seeding and were left to incubate for another 16 h. Cells were fixed with 4% PFA and 
stained with anti-pFAK Y397 (1:80) and with secondary antibodies conjugated to Alexa 
Fluor 488. Coverslips were mounted in Mowiol 4-88 containing DAPI. Cells were 
imaged by confocal microscopy using a 63x oil objective and a microscope (LSM 5 
PASCAL; Carl Zeiss). Images were acquired using LSM image browser software 
(Carl Zeiss) and the number of focal adhesions per cell was counted.  
 
Immunoblotting 
The expression and phosphorylation of focal adhesion proteins (pFAK, FAK, paxilin, 
vinculin, GAPDH and tubulin) was evaluated by immunoblot. Briefly MDA-MB-231 or 
MCF7 cells were seeded in a MatrigelTM-coated 12 well plate. Drugs were added to 
cells at 80% confluence and were left to incubate for 16 h. Cells were lysed with 
RIPA buffer (50 mMTris pH 7.5, 500 mM NaCl, 0.5 mM MgCl2, 0.1 % Triton X-100, 
0.1% SDS, 0.5% sodium deoxycholate, 1 mM EDTA, protease and phosphatase 
inhibitor cocktails. The lysates were cleared by centrifugation (15,000 x g, 15 min), 
resolved using NuPAGE®Novex 4-12% Bis-Tris gels, and transferred onto a 
nitrocellulose membrane. Antigen-antibody complexes were detected and quantified 
using RDye-conjugated secondary antibodies and a LI-COR scanner (Odyssey). The 
primary antibodies used were: anti-pFAK Y397 (1:800), anti-FAK (1:1000), anti-Paxillin 
(1:2500), anti-Vinculin (1:1000), anti-GAPDH (1:5000) and anti-Tubulin (1:7500). 
Band intensity was quantified from three independent assays. 
 
NF-kB gene reporter assay 
Cells in 96-well plates were transfected with 60 ng/well of firefly luciferase NF-kB 
reporter plasmid and 20 ng/well of pTK-Renilla luciferase (pRL-TK) as transfection 
control, using Lipofectamine® LTX Reagent and PLUSTM Reagent, according to the 
manufacturer`s protocol. A plasmid encoding NF-kB-firefly luciferase was a gift from 
R. Hofmeister (University of Regensburg, Germany). Forty-eight hours after 
transfections cells were treated for 16 h with the appropriate drugs and lysed using 
Passive Lysis Buffer. The relative stimulation of reporter-gene expression was 
calculated by normalizing firefly luciferase activity with renilla luciferase activity (both 
measured using a Synergy™ HTX Multi-Mode Microplate Reader). In all cases, data 
shown are representative from at least three independent experiments, each 
comprising five replicates. TNF-a (50 ng/mL) was used as positive control.  
RESULTS 
 
Impact of MnTnHex-2-PyP and dox on cell viability and cell death 
 The effect of MnTnHex-2-PyP and dox on the viability of human mammary cells 
was evaluated by the MTT assay (Fig. 2A and B). The MnP alone, at the biologically 
relevant concentration of 5 μM [19] was not considerably toxic to MCF7 and MDA-
MB-231 cells. Dox exhibited a concentration-response decrease in cell viability in 
both cell lines. However, MDA-MB-231 cells were more resistant to dox toxicity. For 
example, under our experimental conditions, exposure to 5 μM of dox decreased cell 
viability more drastically in MCF7 than in MDA-MB-231 cells (p < 0.001). Dox 
cytotoxicity was not altered by the addition of MnTnHex-2-PyP (5 μM). Cell viability 
studies allowed the identification of non-toxic levels of the compounds. The use of 
clinically relevant [20,21] and non-cytotoxic concentrations is essential when testing 
potential inhibitors of migration/invasion [16,22]. Concentrations of 0.1 μM of dox and 
5 μM of the MnP were selected for the subsequent experiments. To confirm that 
these concentrations did not induce cell death, the percentage of cells in sub-G1 was 
investigated. No differences were found in the Sub-G1 population in either cell line 
treated for 16 h with 0.1 μM of dox and/or 5 μM of the MnP (Fig. 2C-F). The cell cycle 
distribution was similar in MnP-treated and in control cells. However, MDA-MB-231 
cells treated with dox presented a G2/M population increase (*** p < 0.001), 
consistent with previous reports [23]. 
 
MnTnHex-2-PyP and dox modulate intracellular ROS levels 
 Since the biological effects of the MnP are probably associated with the 
modulation of the cellular redox status, the impact of the drugs in the intracellular 
levels of ROS was assessed using the DHE and DHR probes, after 1 or 16 h of drug 
exposure. DHE is a cell permeable probe that reacts with O2
•– to form the fluorescent 
product 2-hydroxyethidium [24]. The oxidation of DHE is mostly superoxide-
dependent and is considered to be quite insensitive to H2O2 [10,25,26]. DHR is 
widely used to evaluate general RS formation, and it is reactive with H2O2 in 
peroxidase-containing cells [24,27]. MCF7 and MDA-MB-231 cells incubated with 
dox, MnP or both drugs, exhibited a significant increase in ROS levels assessed by 
the DHR probe, which was more pronounced after 16 h of drug exposure. Catalase 
counteracted the increased ROS levels caused by the co-treatment with dox and 
MnP (Fig. 3A,C,D), demonstrating that higher ROS was in part due to enhanced 
H2O2 accumulation. DHE fluorescence was significantly increased in dox-treated 
cells, in both cell types and both incubation periods, and this was partially reverted by 
MnP (Fig. 3B,E,F), suggesting an increase in O2
• – in dox-treated cells, as previously 
described [22,25,28].  The intracellular ROS alterations induced by the treatments 
were similar in both cell lines. 
 
Impact of MnTnHex-2-PyP and dox on cell migration  
 Three different assays were used to evaluate the impact of dox and MnP on cell 
migration. Collective cell migration was assessed by wound-healing assays (Fig. 
4A,B). While dox and MnP given alone did not significantly change cell migration, co-
treatment led to a reduction in cell motility. This decrease was more pronounced in 
MCF7 cells, in which the % of wound closure decreased to 0.63 ± 0.09-fold of 
control.  
To explore if H2O2 increased levels are associated with the reduction of collective cell 
migration observed upon the co-treatment with dox+MnP, experiments using CAT 
were performed. The addition of CAT reverted this inhibitory effect of dox+MnP (Fig. 
4A), suggesting a role for H2O2 in mediating this migration phenotype. Chemotaxis 
was evaluated by a transwell assay using FBS as chemoattractant. In both cell types, 
MnP or dox alone did not alter chemotaxis. However, simultaneous exposure to both 
compounds resulted in a significant decrease in chemotactic migration of MCF7 and 
MDA-MB-231 cells to 83.4 ± 7.9% and to 84.3 ± 4.4% of controls, respectively (Fig 
4C,D). Single cell random migration was also evaluated by time-lapse microscopy. 
As expected, the migration speed of MDA-MB-231 cells was higher than that of 
MCF7 cells (Fig. 4E-G, p < 0.001). While the drug treatments did not significantly 
change the random migration of MCF7 cells (Fig. 4E-F), dox promoted the migration 
of MDA-MB-231 cells (p < 0.01 versus control). This increase was reverted by the 
addition of MnP (Fig. 4E, G). In the different conditions tested, no changes in 
migration persistence were observed (data not shown). 
As the drug treatments influenced cell migration, the impact on cell 
adhesion/detachment was also determined. This was assessed by an EDTA-induced 
cell detachment assay, using experimental conditions that induced ~50% cell 
detachment in non-treated cells. Although no significant differences were found, the 
same trend was observed in MCF7 and MDA-MB-231 cells. While dox and the MnP 
did not change cell detachment, the co-exposure slightly reduced it (non-significant; 
data not shown). 
 
Dox and MnTnHex-2-PyP reduce MDA-MB-231 cell invasion  
 Since a critical feature of metastatic cancer cells is their ability to invade tissues, 
the effect of the MnP and dox in cell invasion was evaluated. These experiments 
were only carried out with MDA-MB-231 cells, due to the non-invasive phenotype of 
MCF7 cells [29] (no invasion was observed under our experimental conditions; data 
not shown). Cell invasion was assessed using a transwell assay using FBS as a 
chemoattractant. Treatment with Dox and MnP individually led to a significant 
decrease in cell invasion. The co-treatment with both drugs decreased cell invasion 
to 77.3 ± 3.1% of controls (Fig 5A,B). 
The invasion of cancer cells can be due to proteolytic degradation of ECM or from 
amoeboid cell migration through the ECM components [30]. Therefore, a gelatin 
degradation assay was performed to explore the contribution of the proteolytic 
degradation of ECM to the reduction in cell invasion observed. Treatment with dox or 
with MnP significantly reduced gelatin degradation to 38.4% and 21.7% of controls, 
respectively. The result obtained for dox is in accordance with previous data [31]. 
Treatment with both drugs together had a significantly greater impact on degradation 
inhibition (11.8% of control; Fig. 5C-D). 
 
Impact of MnTnHex-2-PyP and dox on cell spreading 
 As the combination of dox with MnP influenced cell movement, further studies 
were carried out to explore the mechanisms underlying such effects. The analysis of 
cell spreading provides a simple experimental approach to determine general 
functional impacts on cytoskeletal assembly. As shown in Fig. 6A and D, MDA-MB-
231 exhibited more rapid increase in cell area over time following plating as 
compared to MCF7 cells, suggesting more rapid cytoskeletal dynamics and focal 
adhesion turnover, which is compatible with the more migratory phenotype of these 
cells. However, exposure to MnP and/or dox had no effect on the cell spreading 
dynamics (data not shown).  
Cells incubated with dox, MnP or both drugs for 30 mins also showed no difference 
in spread cell area (Fig. 6C,F). Conversely, a 16 h-co-exposure to dox and MnP led 
to an increase in cell area in MDA-MB-231 cells, but not MCF7 (p < 0.05, when the 
impact of dox+MnP in the two cell lines is compared). This increase in cell area was 
significantly reverted by CAT (Fig. 6B,E), suggesting that H2O2 participates in 
dox+MnP-induced cell spreading. 
 
Impact of MnTnHex-2-PyP and dox on focal adhesions number 
Considering the differences in cell migration and cell area observed after treatment, 
the number of focal adhesions per cell was analyzed. In MCF7 cells, dox treatment 
led to a significant increase in the number of FA per cell (p < 0.05), while other 
conditions had no effect (Fig. 7A,B). Dox also increased the number of FA in MDA-
MB-231 cells (p < 0.01, Fig. 7C,D). The increase was more evident in cells co-treated 
with dox and MnP (p < 0.001 versus control), suggesting a possible mechanistic link 
between the observed changes in cell area and in the number of FA. While treatment 
of MCF7 cells with dox+MnP only increased the number of focal adhesions by 7% 
when compared with control, an increase of 37% was observed in MDA-MB-231. 
Comparing the impact of this treatment in both cell lines, a significantly difference 
was clear (p < 0.001). 
 
Impact of MnTnHex-2-PyP and dox on the expression of focal adhesion 
proteins  
Since the drug treatments altered the number of FA, the levels of several proteins 
involved in the focal adhesion complexes were evaluated by immunoblotting (IB). For 
both cell lines, the exposure to dox and/or MnP did not significantly alter the levels of 
FAK, pFAK, vinculin, and paxillin (Fig. 8). 
 
Impact of MnTnHex-2-PyP and dox on NF-kB activation 
Alterations in intracellular levels of H2O2 modulate various signaling pathways, such 
as NF-kB [32]. This transcription factor is highly relevant for cell migration and 
invasion [33–36]. NF-kB activation upon treatment with dox and/or MnP was 
evaluated using a luciferase-based gene reporter assay. In MCF7 cells, dox and 
MnP alone increased NF-kB activation by approximately 2-fold, while the co-
treatment led to a reduction to levels similar to those of non-treated cells (Fig. 9A). In 
MDA-MB-231 cells, dox and MnP, per se, did not change NF-kB activation. 
Conversely, the combined treatment led to a significant increase (Fig. 9B). This 
finding is in accordance with the study of Shah et al. [37], who demonstrated that the 
addition of an MnP to MDA-MB-231 enhanced H2O2 levels leading to an increase in 
NF-kB activity. 
DISCUSSION 
 
SODm are currently being tested in different clinical trials, in combination with 
chemo- or radiotherapy, due to their capability of boosting anticancer treatments, 
while protecting non-tumor tissues from ROS-mediated side effects [4]. However, 
only very scarce data is available regarding the impact of SODm in cell migration and 
invasion, which are determinant features of cancer progression and prognosis. 
Regarding native SOD enzymes, their effects in cancer metastases are still unclear. 
In many conditions, including the advanced breast cancer, SOD seems to promote 
cancer progression and aggressiveness [5,6]. This fact raises some concerns on the 
use of SODm in cancer treatment, justifying the need to comprehend the effects of 
SODm in cellular processes related with the formation of metastases. 
O’Leary et al. [38] showed that the SODm GC4419 significantly decreases the 
invasive capacity of pancreatic ductal adenocarcinoma cells. Tong et al. [39] have 
shown that MnTE-2-PyP (30 μM) reduced the migration and invasion of prostate 
cancer cells. Recently, an in vivo study conducted by Chatterjee el al. [40] showed 
that MnTE-2-PyP did not affect the metastatic progression of PC3 cells in an 
orthotopic prostate tumor model. On the other hand, in a mouse D-245MG glioma 
xenograft model, down-regulation of metastatic pathways was observed upon 
treatment with MnP + radiation vs radiation only [41]. Regarding breast cancer, our 
group has previously shown that a macrocyclic copper(II) complex with superoxide 
scavenger activity decreased MCF7-directed cell migration and, in combination with 
dox, reduced the invasion of MDA-MB-231 cells [22]. Shah et al. [37] reported that 
the SODm EUK134 reduced the adhesion of MDA-MB-21 cells and the chemotaxis 
of MCF7 and MDA-MB-231 cells. However, these results were observed at cytotoxic 
concentrations of EUK134. In the same report, MnTM-4-PyP was also studied. This 
MnP decreased the adhesion and enhanced the chemotaxis of MDA-MB-231 cells, 
while in MCF7 only a minor decrease in chemotactic migration was observed [37]. 
The few available studies are insufficient to draw conclusions on the impact of SODm 
in breast cancer metastases. Therefore, we herein studied the potential impact of the 
SODm MnTnHex-2-PyP in cancer cells migration in the breast cancer models MCF-7 
(non-invasive) and MDA-MB-231 cells (invasive). Importantly, these studies were 
carried out at concentrations that did not impair cell viability. Although the use of low 
concentrations may lead to less pronounced effects, this is a technical requirement 
for an accurate evaluation of changes in the migratory phenotype, excluding the 
influence of cytotoxicity. Moreover, the concentrations used in this work are 
biologically relevant. A pharmacokinetic study of this MnP carried out in mice found 
plasma and tissue concentrations in the order of magnitude of low micromolar [19]. 
Regarding dox, the concentration used herein is in the range of steady-state plasma 
concentrations (25-250 nM) observed in patients after standard bolus infusion 
[20,21]. 
In this work, the intracellular ROS levels observed are compatible with the SOD-like 
activity of MnP. MnP decreased superoxide and increased H2O2, which is in 
accordance with previous studies [37,39]. Cells co-treated with MnP and dox showed 
increased ROS levels, at least partially due to an increase in H2O2. Previous studies 
have suggested that both O2
• – and H2O2 are relevant for the regulation of cell 
migration [33]. While H2O2 seems to be a key signaling molecule in this process, the 
exact impact of H2O2 is still unknown and may vary with the cell type, concentrations, 
and specific conditions, justifying the contradictory reports found in the literature [42–
45]. As different types of cell migration have been described in breast cancer [46,47], 
our study also addressed different types of cell migration. The MnP, when used as a 
single agent, did not impact on collective, chemotactic or random cell migration. 
Regarding dox, an increase in random migration was observed, along with an 
increase in the number of focal adhesions. Although contradictory data can be found 
in the literature [31,48,49], several reports demonstrate that dox might promote 
migratory and invasive phenotypes. Regarding breast cancer, Bandyopadhyay et al. 
[50] have described that dox increased cell migration and invasion in breast cancer 
cells, and it induced lung metastasis of human breast cancer cells. In addition, Niu et 
al. [36] observed a marked increase in MDA-MB-231 cells migration and 
invasiveness upon treatment with dox. These effects might be critical in cells that 
contact with lower drug concentrations and therefore remain viable after 
chemotherapy. Importantly, we herein showed that the addition of MnP counteracted 
most of the dox-induced effects, suggesting potential clinical benefits of combining 
dox with MnP. In other endpoints, MnP and dox showed a synergistic effect. 
Comparing with non-treated cells, the co-treatment with dox and MnP exhibited 
beneficial effects by reducing collective cell migration and chemotaxis. These 
differences might be partially explained by the alterations detected in cell area and 
FA number. Cell invasion is a particular type of cell migration particularly relevant in 
the metastization process. The drugs under study reduced proteolytic MDA-MB-231 
cell invasion, especially in combination. 
NF-kB is a redox-regulated transcription factor, highly relevant for cell migration and 
invasion [33–36]. Previous studies showed that MnP can modulate NF-kB activity 
[41] by a direct pro-oxidative effect in this transcription factor subunits that affects 
DNA-binding properties [51], but also indirectly by increasing H2O2 production [37]. 
The dose-dependence and the exact mechanism behind NF-kB regulation by MnPs 
are still under investigation. H2O2 cannot be simply defined as a NF-kB inducer but 
should instead be considered as a fine-tuning modulator of NF-kB activation pathway 
by other agents [32]. The differential results observed in the two cell lines may be 
attributed to the inherent differences in peroxide levels and in antioxidant enzymes of 
MCF7 and MDA-MB-231 cells [22,52,53]. Moreover, in the MDA-MB-231 cells, NF-
kB is constitutively activated, contributing to the aggressive phenotype of these cells 
[54,55].  
Although we have obtained differential results, depending on cell line and migration 
type, the alterations induced by MnP in dox-treated cells were consistently towards a 
therapeutically favorable effect on cell phenotype. These data contribute to 
substantiate the usefulness and safety of SODm-based treatments in breast cancer 
therapy.  
 
 
FIGURE LEGENDS 
 
Figure 1 – Chemical structure of MnTnHex-2-PyP5+ [9] 
 
Figure 2 – Treatment with MnP and low concentrations of dox does not induce 
cell death. MCF7 (A, C and E) and MDA-MB-231 (B, D and F) cell viability and cell 
death induction following exposure to the indicated MnP and dox concentrations for 
16 h, were evaluated by an MTT assay (A and B) and a DNA content assay after cell 
fixation (C-F), respectively. Histograms show representative MCF7 and MDA-MB-
231 DNA content profiles following exposure to dox (0.1 μM), MnP (5 μM) or both, 
fixation and PI stain (C-D). Summary results from cell viability (A and B) and DNA 
content assays (E and F) are represented as means ± SD from three independent 
experiments. PI, propidium iodide. 
 
Figure 3 – MnP and dox lead to an increase in intracellular ROS. Intracellular 
ROS levels were determined in MCF7 (A, B, C and E) or MDA-MB-231 (D and F) 
cells treated with the indicated drugs (dox (0.1 μM), MnP (5 μM)) for 16 h. 
Fluorescence microscopy images show representative MCF7 cells after 25-min 
incubation with DHR and DHE (A and B). Scale bars = 20 μm. Summary results 
(means ± SD from three independent experiments) show relative DHR and DHE 
fluorescence (C to F). *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA with 
Tukey’s test, relative to untreated cells). 
 
Figure 4 – MnP and dox can reduce chemotaxis and random and collective cell 
migration. Collective cell migration, chemotaxis and random migration of MCF7 (A, 
C and F) or MDA-MB-231 (B, D and G) cells treated with the indicated drugs (dox 
(0.1 μM), MnP (5 μM) for 16 h) were measured. Collective cell migration was 
measured by the wound healing assay (A and B), chemotaxis was measured using a 
transwell system with FBS as chemoattractant (C and D) and random cell migration 
on matrigel was measured using time lapse microscopy (F and G). Tracks of 
individual migrating cells (n = 60 for each condition) used to measure random cell 
migration are shown in E. Migration rates (A-D and F-G) are shown as means ± SD. 
*p < 0.05, **p < 0.01 (Student’s t-test, relative to untreated cells).  
 
Figure 5 – Treatment with MnP and dox reduces MDA-MB-231 cell invasion and 
extracellular proteolytic activity. MDA-MB-231 cells were seeded on matrigel-
coated transwells and were allowed to invade for 16 h in the presence of the 
indicated drugs (dox (0.1 μM), MnP (5 μM)) (A). The percentage of invading cells is 
summarized in B. The extracellular proteolytic activity was measured using a 
fluorescent gelatine degradation assay (C). Invasion rates (B), and normalized 
gelatine degradation (D) from at least three independent experiments are shown as 
means ± SD. *p < 0.05, **p < 0.01 (Student’s t-test, relative to untreated cells). 
 
Figure 6 – Co-treatment with MnP and dox increases cell area. MCF7 and MDA-
MB-231 cell spread on matrigel was monitored over time (A and D). Cells treated 
with the indicated drugs for 16 h (B and E) or 30 min (C and F) were seeded on 
matrigel-coated transwells and allowed to spread. The cells were left to adhere for 12 
h and cell area was measured. Data is summarised in B, C, E and F. Cell area 
determined from at least three independent experiments (n > 50 cells per condition 
and per experiment) and are shown as means ± SEM. *p < 0.05, **p < 0.01 (one-way 
ANOVA with Tukey’s test, relative to untreated cells). 
 
Figure 7 – Effect of MnP and dox on the number of focal adhesions. Confocal 
images show MCF7 (A) and MDA-MB-231 (C) cells treated with the indicated drugs 
for 16 h, fixed and stained with anti pFAK. Images are typical of three independent 
experiments. Scale bars, 20 μm. Summary results (means ± SEM from ≥90 cells for 
each condition) show numbers of focal adhesions per cell, determined by counting 
pFAK positive spots (B and D). *p < 0.05, **p < 0.01 (one-way ANOVA with Tukey’s 
test, relative to untreated cells).  
 
Figure 8 – Effect of MnP and dox treatment on the levels of FA proteins. Typical 
IB showing total pFAK, FAK, Paxillin and Vinculin and the loading controls (GAPDH 
and Tubulin) for MCF7 and MDA-MB-231 cells treated with the indicated drugs for 16 
h (A). Summary results (means ± SD from three independent experiments) show 
relative protein expression levels for MCF7 cells (B) and MDA-MB-231 cells (C). 
 
Figure 9 – Effect of MnP and dox treatment on NF-kB-dependent transcription. 
MCF7 (A) and MDA-MB-231 (B) cells transfected with a firefly luciferase reporter 
plasmid under the control of an NF-kB-dependent promoter and a renilla luciferase 
transfection control were treated with the indicated drugs for 16 h. Data are from one 
experiment representative of at least three, each performed in 5 replicates are 
presented as means ± SD, *p < 0.05; **p < 0.01; *** p < 0.001 (one-way ANOVA with 
Tukey’s test), compared with untreated cells (-ve). 
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